Companies Dominating the Essential Thrombocythemia Landscape
- Active Biotech AB
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Incyte
- Bayer AG
- USV Private Limited.
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca
- Takeda Pharmaceutical Company Limited
Browse Key Market Insights with Data Illustration:
In the News
- Active Biotech AB announced the approval for tasquinimod Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of myelofibrosis. It creates an important regulatory channel and gives us the opportunity to rapidly progress tasquinimod development in this patient population.
- Incyte has announced to receive data from two Limber trials assessing single-agent therapy and combination treatments in patients with myelofibrosis (MF) using ruxolitinib with parsaclisib.
